期刊文献+

重症患者组织标本病原微生物分析

The distribution of pathogenic microorganisms in clinical tissue specimens of patients with severe infection
下载PDF
导出
摘要 目的通过针对重症感染患者组织标本病原微生物分析,了解临床致病微生物分布。方法收集2019年1至6月95例重症感染病人组织标本行细菌学和药敏检测、分析。结果来自95例样本的有效组织标本共2803份,555份有阳性结果,阳性率为19.9%。各类型的组织标本培养阳性的细菌共11种,分别为铜绿假单胞菌、肺炎克雷伯菌、鲍曼不动杆菌、洋葱伯克霍尔德氏菌、粪肠球菌、金黄色葡萄球菌、奇异变形杆菌、表皮葡萄球菌、嗜麦芽窄食单胞菌、屎肠球菌和大肠杆菌。在本研究的时间段内送检标本阳性最多的依次为痰液、尿液和全血;常见的5个菌种依次为铜绿假单胞菌、鲍曼不动杆菌、肺炎克雷伯菌、粪肠球菌和洋葱伯克霍尔德氏菌。痰组织标本中阳性微生物例数最多,为373份,穿刺液标本获取的阳性例数最少,为1例。总体而言,铜绿假单胞菌仍是本次收集组织样本分析获取的最多菌属(共182份),大肠杆菌和嗜麦芽窄食单胞菌最少(分别为7份和11份)。结论个别致病菌的常驻和耐药是重症医学的临床难题,需要严格个体化管控。 Objective To investigate the distribution of pathogenic microorganisms in clinical tissue specimens of patients with severe infection.Methods A total of 95 patients with severe infection who were treated in our hospital from January to June 2019 were enrolled in the study,and the tissue specimens were collected,and drug sensitivity testing and analysis were performed.Results A total of 2803 specimes were collected,in which,555 specimens were positive,with posituve rate being 19.9%.And 11 kinds of pathogenic bacteria were detected,which were Pseudomonas aeruginosa,klebsiella pneumoniae,Acinetobacter baumannii,Enterococcus faecalis,Staphylococcus aureus,Escherichia coli.etc.The positive rate of microorganisms in phlegm specimens was the highest(373 specimens).Moreover Pseudomonas aeruginosa,Acinetobacter baumannii and Klebsiella pneumoniae were particularly prominent.Conclusion The resident and drug resistance of individual pathogenic bacteria is a clinical problem in ICU,which requires strict individualized control.
作者 姜健 张芳 赵鑫宇 甄根深 王冠 翁以炳 JIANG Jian;ZHANG Fang;ZHAO Xinyu(Department of Critical Care Medicine,Beijing Luhe Hospital affiliated to Capital Medical University,Beijing 101104,China;不详)
出处 《河北医药》 CAS 2021年第8期1165-1169,共5页 Hebei Medical Journal
基金 北京市通州区科学技术委员会临床特色专项项目(编号:KJ2018CX009-08)。
关键词 重症患者 组织标本 病原微生物 药敏检测 critical cases histological specimen pathogenic microorganism drug sensitivity test
  • 相关文献

参考文献3

二级参考文献34

  • 1吴杨冰.抗菌药物不合理使用处方分析[J].医药导报,2006,25(3):262-263. 被引量:12
  • 2肖永红.加强专业人员知识培训是抗菌药物合理应用重要措施[J].临床药物治疗杂志,2007,5(6):31-35. 被引量:35
  • 3遏制细菌耐药国家行动计划(2016-2020年)[Z]. 2016. 被引量:1
  • 4National action plan on antimicrobial resistance 2016 to 2020[Z]. 2016. 被引量:1
  • 5Declaration of the G7 Health Ministers 8-9 October 2015 in Berlin[EB/OL]. [2016-08-05]. http://www.bmg.bund.de/fileadmin/dateien/Downloads/G/G7-Ges.Minister_2015/G7_Health_Ministers_Declaration_AMR_and_EBOLA.pdf. 被引量:1
  • 6Antibiotic resistance a global threat to health, economy: expert[EB/OL]. (2015-06-16)[2016-08-05].http://www.globaltimes.cn/content/927294.shtml. 被引量:1
  • 7LaxminarayanR, Amábile-CuevasCF, CarsO, et al. UN High-Level Meeting on antimicrobials--what do we need?[J]. Lancet, 2016,388(10041): 218-220. DOI: 10.1016/S0140-6736(16)31079-0. 被引量:1
  • 8WHO. Global action plan on antimicrobial resistance[EB/OL]. [2016-08-05]. http://www.who.int/drugresistance/global_action_plan/en/. 被引量:1
  • 9ZhangJ, YuW, ZhaoLL, et al. Epidemiology and characteristics of bacterial resistance in China[J]. Chin J Clin Infect Dis, 2016, 9(2): 118-128. DOI: 10.3760/cma.j.issn.1674-2397.2016.02.005. 被引量:1
  • 10LiuYY, WangY, WalshTR, et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study[J]. Lancet Infect Dis, 2016, 16(2): 161-168. DOI: 10.1016/S1473-3099(15)00424-7. 被引量:1

共引文献471

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部